Avaliação da eficácia da eritropoetina humana recombinante no controle de anemias em paciente hemodialisados

• Ano de defesa: 2016
• Autor(a) principal: Sobral Júnior, Paulo
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Palavras-chave em Português: Pacientes; Anemia; Hematócrito; Hemoglobinas; Eritropoetina
• Link de acesso: http://www.repositorio.ufc.br/handle/riufc/17566

Chronic kidney disease is characterized by renal impairment of glomerular function, tubular and endocrine, slow, progressive and irreversible, with anemia as a major complication, whose intensity and prevalence are related to the stage of kidney disease and disability in production erythropoietin (EPO). Treatment with erythropoietin recombinant human (rHuEPO) is now used worldwide and has satisfactory response in the regulation of hemoglobin levels. The aim of this study was to evaluate the efficacy of rHuEPO in hemodialysis patients through assessment and correlation of haematological parameters erythrocyte line (red blood cells, hematocrit and hemoglobin), and biochemical (iron and ferritin). For this proposition, we evaluated two distinct groups, one test group, with 77 patients who made use of rHuEPO for three weeks, and a second control group, with 38 patients who did not use this treatment, totaling 115 people. Data were statistically analyzed in spreadsheet Microsoft Office Excel 2010 program Epi-Info 4.1, Student's t-test, and Graph Pad Prism program, version 5.0, with Pearson's chi-square correlation through SPSS, version 10.0. The considered confidence interval was 95% and significance in * p <0.05. In the group rHuEPO employed, during three weeks, there was an increase in hemoglobin from baseline in the order of 3.3% seven days; 30.6% fourteen days; and 46.9% with twenty-one days. Hematocrit increased 3.5% seven days; 30.9% fourteen days; 47.2% with twenty-one days. Red blood cells increased by 4.5% seven days; 31.8% fourteen days; and 50% with twenty-one days. The same parameters were evaluated for the group that did not rHuEPO in this, there was no statistically significant change. As for the biochemical aspects of iron and ferritin, examined in this study, there was no relevance in the two groups and no difference between them. It follows that rHuEPO is effective for the increase of hemoglobin, hematocrit and red blood cells, and that as the level of iron and ferritin were within the reference values ​​for the two groups, an analysis of hematological parameters in the use of rHuEPO it was not compromised, reaching a variation of hemoglobin, the end of the third week of 2.92 g / dL, confirming the efficacy of treatment with rHuEPO.